Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA-1: DA-302168S in Overweight/Obese Participants
NCT07629544Phase 3Recruiting
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 3 trial of DA-302168S in obesity, sponsored by Chengdu Diao Pharmaceutical Group. Started Jun 2026; status: recruiting.
02
Drugs
DA-302168S
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07629544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629544.